u/RunTechnical6837

تجيني مشاعر انثوية لما اشوف اولاد اجسامهم حلوة وطوال كأني بنت ولكن الشعور ذا لاعمار معينة واجسام معينة هل بكذا اعتبر ترانس؟؟

بسم الله الرحمن الرحيم

ماهو القطاع او السهم الذي تتوقع انه بيرتفع فوق 10 اكس ان شاء الله خلال ثلاث الى خمس سنوات من الان طبعا هذه وجهة نظر شخصية لكل مشارك ماهي توصية

شروط الاختيار :

اذكر سهم واحد فقط (ماينفع تطرح ثلاث اربعة اسهم ويلا لا)
علل اجابتك (ليش تتوقع بيرتفع ١٠ اضعاف بإذن الله)

وبأبدأ بنفسي وطبعا هذه وجهة نظر شخصية ماهي توصية شراء او بيع وكل مسؤول عن قراره

القطاع : استخراج الذهب والفضة

السهم vzla

الاسباب :

جاذبية منجم بانوكو كعائد واستثمار
التوترات الجيو سياسية وارتفاع الدين العالمي وضعف الثقة في العملات الورقية مما سيسهم في ارتفاع الذهب والفضة والله اعلم

Let me begin with an important disclaimer: this is my personal interpretation of the appointment, not a claim that Helus has received an acquisition offer or is currently negotiating a sale. There is no public evidence confirming that.
However, after reviewing Michael Halstead’s actual transaction history—and, more importantly, the SEC filing describing his role in the sale of Intra-Cellular Therapies—I believe Helus may be preparing for more than just commercialization.
**This is a very specific type of CEO appointment**
Michael Halstead is not primarily a drug-discovery scientist. He is a lawyer, corporate-development executive, operational leader and pharmaceutical transaction specialist.
His career includes involvement in three major pharmaceutical transactions:
Warner Chilcott’s approximately **$3.1 billion acquisition of Procter & Gamble****’****s global pharmaceutical business**, followed by the integration of roughly 2,000 employees and multinational operations.
Warner Chilcott’s approximately **$8.5 billion sale to Actavis**.
Intra-Cellular Therapies’ **$14.6 billion sale to Johnson & Johnson**.
At Warner Chilcott, Halstead became Senior Vice President of Corporate Development and assumed leadership of the company’s business-development activities. At Intra-Cellular, he joined as General Counsel, gradually took responsibility for multiple operational functions, became President in 2024 and was directly involved in the Johnson & Johnson transaction.
**His role in the Johnson & Johnson negotiation matters**
The most interesting evidence comes from Intra-Cellular’s merger proxy filed with the SEC.
Johnson & Johnson initially offered **$115 per share** in December 2024. Intra-Cellular’s board concluded that the proposal significantly undervalued the company but agreed to provide a limited amount of due-diligence information in the hope that J&J would improve its offer.
Halstead then became one of the central contacts in the process. He coordinated the delivery of high-priority diligence materials and spoke directly with J&J’s global head of business development.
On December 19, Halstead told J&J that it would have to increase its offer before Intra-Cellular would provide any additional diligence information.
That is not a minor administrative role. He was helping the company control access to its information and use that access as negotiating leverage.
J&J eventually increased its offer from **$115 to $126.50**, and finally to **$132 per share**. That was a 15% increase from the initial proposal and produced a final equity value of approximately **$14.6 billion**.
To be precise, Halstead was not the only person negotiating the transaction. CEO Sharon Mates, the board, Centerview, Jefferies and legal counsel all played important roles, and Mates handled the final price discussions with J&J’s CEO. But the SEC record clearly shows that Halstead was directly involved in the process and personally communicated the company’s refusal to proceed at the initial price.
**Why appoint him now?**
The timing is what makes this appointment particularly interesting.
Helus has completed enrollment in APPROACH, the first pivotal Phase 3 study of HLP003 as an adjunctive treatment for major depressive disorder. Topline results remain expected in **Q4 2026**. EMBRACE, the second pivotal study, continues enrolling, while EXTEND is collecting longer-term safety and durability data.
HLP003 has already received FDA Breakthrough Therapy Designation. In Phase 2, the company reported a 14.08-point placebo-adjusted MADRS benefit at the three-week primary endpoint, followed by durable results in longer-term follow-up.
Therefore, Helus is approaching the most important value-inflection event in its history.
The straightforward explanation is that Halstead was recruited to build Helus into an independent commercial pharmaceutical company. Helus itself emphasized his experience in late-stage development, infrastructure buildout, financing, manufacturing, supply chains and commercialization.
That explanation is entirely plausible.
But I do not believe it excludes a second mandate: preparing the company to evaluate and negotiate strategic alternatives if HLP003 produces compelling Phase 3 results.
The same executive can prepare a company for commercialization while also making it a better-organized, more credible and more valuable acquisition target. In fact, showing that Helus can commercialize independently may strengthen its negotiating position because it reduces the pressure to accept an inadequate offer.
**Could an interested buyer already be watching?**
There is no public evidence that Helus currently has an offer on the table.
Still, I would not be surprised if major pharmaceutical companies had already expressed preliminary interest or were monitoring the program closely. Large companies do not necessarily wait for a formal Phase 3 announcement before beginning internal evaluations, building valuation models or establishing relationships with management.
My theory is that Helus may prefer to move through its next corporate updates and, most importantly, obtain the APPROACH results before seriously considering a transaction.
Positive Phase 3 data would materially reduce clinical risk and could give Halstead far more leverage than the company has today. If an interested party approached before the data, Helus could potentially delay a decision, provide only limited information or structure discussions around a higher valuation contingent on the Phase 3 outcome.
That would resemble the type of disciplined information control Halstead used during the Intra-Cellular process.
**Is a $4–5 billion acquisition valuation unrealistic?**
I do not think a **$4–5 billion valuation** is impossible after exceptionally strong Phase 3 results, although I would not describe it as guaranteed or even as my base-case outcome today.
The most relevant recent comparison is **Eli Lilly****’****s July 2026 agreement to acquire AtaiBeckley**.
Lilly agreed to pay approximately **$2.8 billion upfront**, plus contingent value rights potentially worth another **$1 billion**, producing a maximum potential consideration of approximately **$3.8 billion**.
AtaiBeckley was still a clinical-stage company. Its lead asset, BPL-003, had produced positive Phase 2b results in treatment-resistant depression and had initiated Phase 3 activities. The acquisition also included VLS-01 in Phase 2 and other pipeline assets.
BPL-003’s Phase 2b study met its primary and key secondary endpoints, but the company had not yet produced pivotal Phase 3 efficacy results when Lilly agreed to the acquisition.
That transaction is important because it provides recent market validation for next-generation serotonergic treatments in depression.
If HLP003 produces genuinely strong, clean and reproducible Phase 3 data, Helus could potentially offer a buyer:
A Phase 3, Breakthrough Therapy-designated asset targeting adjunctive MDD.
A potentially broader commercial population than treatment-resistant depression alone.
HLP004 as a second clinical asset in generalized anxiety disorder.
A large intellectual-property portfolio.
A development platform extending beyond one molecule.
An experienced CEO who understands commercial preparation, financing, due diligence and pharmaceutical M&A.
Under those conditions, a valuation above AtaiBeckley’s $2.8 billion upfront consideration could become defensible. A **$4–5 billion outcome** would be especially conceivable if the data were unusually strong, the safety and treatment model remained commercially practical, and more than one potential buyer became interested.
However, one successful APPROACH result would not eliminate all risk. EMBRACE would still be ongoing, regulatory approval would not be guaranteed, and the commercial treatment infrastructure would still need to be demonstrated. A buyer might therefore prefer a structure containing both upfront cash and milestone-based contingent payments, similar to the AtaiBeckley transaction.
**My conclusion**
I am not saying Helus hired Michael Halstead solely to sell the company.
He is highly qualified to prepare HLP003 for regulatory submission and commercialization, and Helus may fully intend to remain independent.
But I also do not believe his transaction history should be dismissed as a coincidence.
Helus appointed a CEO who has participated in a major pharmaceutical acquisition, two major corporate exits, multiple equity offerings, multinational integration and a direct negotiation process in which the initial buyer was explicitly told to raise its price.
The appointment gives Helus strategic optionality.
If APPROACH succeeds, Halstead can help build the commercial company.
If a major pharmaceutical company makes an attractive approach, he can help evaluate it.
And if the initial offer undervalues Helus, he has already demonstrated that he is willing to tell one of the world’s largest pharmaceutical companies: **the price must go higher.**
That is why I believe this appointment may be about more than simply hiring a new CEO.
It may be about ensuring that, if Helus is eventually sold, shareholders do not leave billions of dollars on the negotiating table.
What do you think: was Halstead appointed mainly to commercialize HLP003 independently, or is the board also positioning Helus for a potential acquisition following the Phase 3 readoutو?

Let me begin with an important disclaimer: this is my personal interpretation of the appointment, not a claim that Helus has received an acquisition offer or is currently negotiating a sale. There is no public evidence confirming that.
However, after reviewing Michael Halstead’s actual transaction history—and, more importantly, the SEC filing describing his role in the sale of Intra-Cellular Therapies—I believe Helus may be preparing for more than just commercialization.
This is a very specific type of CEO appointment
Michael Halstead is not primarily a drug-discovery scientist. He is a lawyer, corporate-development executive, operational leader and pharmaceutical transaction specialist.
His career includes involvement in three major pharmaceutical transactions:
Warner Chilcott’s approximately $3.1 billion acquisition of Procter & Gamble**’s global pharmaceutical business, followed by the integration of roughly 2,000 employees and multinational operations.
Warner Chilcott’s approximately $8.5 billion sale to Actavis.
Intra-Cellular Therapies’ $14.6 billion sale to Johnson & Johnson.
At Warner Chilcott, Halstead became Senior Vice President of Corporate Development and assumed leadership of the company’s business-development activities. At Intra-Cellular, he joined as General Counsel, gradually took responsibility for multiple operational functions, became President in 2024 and was directly involved in the Johnson & Johnson transaction.
His role in the Johnson & Johnson negotiation matters
The most interesting evidence comes from Intra-Cellular’s merger proxy filed with the SEC.
Johnson & Johnson initially offered $115 per share in December 2024. Intra-Cellular’s board concluded that the proposal significantly undervalued the company but agreed to provide a limited amount of due-diligence information in the hope that J&J would improve its offer.
Halstead then became one of the central contacts in the process. He coordinated the delivery of high-priority diligence materials and spoke directly with J&J’s global head of business development.
On December 19, Halstead told J&J that it would have to increase its offer before Intra-Cellular would provide any additional diligence information.
That is not a minor administrative role. He was helping the company control access to its information and use that access as negotiating leverage.
J&J eventually increased its offer from $115 to $126.50, and finally to $132 per share. That was a 15% increase from the initial proposal and produced a final equity value of approximately $14.6 billion.
To be precise, Halstead was not the only person negotiating the transaction. CEO Sharon Mates, the board, Centerview, Jefferies and legal counsel all played important roles, and Mates handled the final price discussions with J&J’s CEO. But the SEC record clearly shows that Halstead was directly involved in the process and personally communicated the company’s refusal to proceed at the initial price.
Why appoint him now?
The timing is what makes this appointment particularly interesting.
Helus has completed enrollment in APPROACH, the first pivotal Phase 3 study of HLP003 as an adjunctive treatment for major depressive disorder. Topline results remain expected in Q4 2026. EMBRACE, the second pivotal study, continues enrolling, while EXTEND is collecting longer-term safety and durability data.
HLP003 has already received FDA Breakthrough Therapy Designation. In Phase 2, the company reported a 14.08-point placebo-adjusted MADRS benefit at the three-week primary endpoint, followed by durable results in longer-term follow-up.
Therefore, Helus is approaching the most important value-inflection event in its history.
The straightforward explanation is that Halstead was recruited to build Helus into an independent commercial pharmaceutical company. Helus itself emphasized his experience in late-stage development, infrastructure buildout, financing, manufacturing, supply chains and commercialization.
That explanation is entirely plausible.
But I do not believe it excludes a second mandate: preparing the company to evaluate and negotiate strategic alternatives if HLP003 produces compelling Phase 3 results.
The same executive can prepare a company for commercialization while also making it a better-organized, more credible and more valuable acquisition target. In fact, showing that Helus can commercialize independently may strengthen its negotiating position because it reduces the pressure to accept an inadequate offer.
Could an interested buyer already be watching?
There is no public evidence that Helus currently has an offer on the table.
Still, I would not be surprised if major pharmaceutical companies had already expressed preliminary interest or were monitoring the program closely. Large companies do not necessarily wait for a formal Phase 3 announcement before beginning internal evaluations, building valuation models or establishing relationships with management.
My theory is that Helus may prefer to move through its next corporate updates and, most importantly, obtain the APPROACH results before seriously considering a transaction.
Positive Phase 3 data would materially reduce clinical risk and could give Halstead far more leverage than the company has today. If an interested party approached before the data, Helus could potentially delay a decision, provide only limited information or structure discussions around a higher valuation contingent on the Phase 3 outcome.
That would resemble the type of disciplined information control Halstead used during the Intra-Cellular process.
Is a $4–5 billion acquisition valuation unrealistic?
I do not think a $4–5 billion valuation is impossible after exceptionally strong Phase 3 results, although I would not describe it as guaranteed or even as my base-case outcome today.
The most relevant recent comparison is Eli Lilly’**s July 2026 agreement to acquire AtaiBeckley.
Lilly agreed to pay approximately $2.8 billion upfront, plus contingent value rights potentially worth another $1 billion, producing a maximum potential consideration of approximately $3.8 billion.
AtaiBeckley was still a clinical-stage company. Its lead asset, BPL-003, had produced positive Phase 2b results in treatment-resistant depression and had initiated Phase 3 activities. The acquisition also included VLS-01 in Phase 2 and other pipeline assets.
BPL-003’s Phase 2b study met its primary and key secondary endpoints, but the company had not yet produced pivotal Phase 3 efficacy results when Lilly agreed to the acquisition.
That transaction is important because it provides recent market validation for next-generation serotonergic treatments in depression.
If HLP003 produces genuinely strong, clean and reproducible Phase 3 data, Helus could potentially offer a buyer:
A Phase 3, Breakthrough Therapy-designated asset targeting adjunctive MDD.
A potentially broader commercial population than treatment-resistant depression alone.
HLP004 as a second clinical asset in generalized anxiety disorder.
A large intellectual-property portfolio.
A development platform extending beyond one molecule.
An experienced CEO who understands commercial preparation, financing, due diligence and pharmaceutical M&A.
Under those conditions, a valuation above AtaiBeckley’s $2.8 billion upfront consideration could become defensible. A $4–5 billion outcome would be especially conceivable if the data were unusually strong, the safety and treatment model remained commercially practical, and more than one potential buyer became interested.
However, one successful APPROACH result would not eliminate all risk. EMBRACE would still be ongoing, regulatory approval would not be guaranteed, and the commercial treatment infrastructure would still need to be demonstrated. A buyer might therefore prefer a structure containing both upfront cash and milestone-based contingent payments, similar to the AtaiBeckley transaction.
My conclusion
I am not saying Helus hired Michael Halstead solely to sell the company.
He is highly qualified to prepare HLP003 for regulatory submission and commercialization, and Helus may fully intend to remain independent.
But I also do not believe his transaction history should be dismissed as a coincidence.
Helus appointed a CEO who has participated in a major pharmaceutical acquisition, two major corporate exits, multiple equity offerings, multinational integration and a direct negotiation process in which the initial buyer was explicitly told to raise its price.
The appointment gives Helus strategic optionality.
If APPROACH succeeds, Halstead can help build the commercial company.
If a major pharmaceutical company makes an attractive approach, he can help evaluate it.
And if the initial offer undervalues Helus, he has already demonstrated that he is willing to tell one of the world’s largest pharmaceutical companies: the price must go higher.
That is why I believe this appointment may be about more than simply hiring a new CEO.
It may be about ensuring that, if Helus is eventually sold, shareholders do not leave billions of dollars on the negotiating table.
What do you think: was Halstead appointed mainly to commercialize HLP003 independently, or is the board also positioning Helus for a potential acquisition following the Phase 3 readoutو?

Helus Pharma has once again discovered the perfect chief executive.
This time, it is Michael Halstead, former President of Intra-Cellular Therapies. To be fair, Halstead brings serious credentials: 25 years of industry experience, involvement in the development and commercialization of CAPLYTA, and senior leadership during Intra-Cellular’s $14.6 billion sale to Johnson & Johnson. This is not a weak appointment on paper.
But Helus shareholders may be forgiven for experiencing a little déjà vu.
On February 10, the company appointed Michael Cola with similarly enthusiastic language, presenting him as an exceptionally qualified leader for Helus’s next phase of growth, execution, commercialization, and shareholder value creation. On April 20—just 69 days later—the Board requested his immediate departure, offered no meaningful explanation, and returned Eric So to the interim CEO position.
So congratulations to Mr. Halstead. His résumé is impressive, and he may genuinely prove to be an excellent CEO.
The more important question, however, is whether Helus’s Board has finally learned how to select, empower, and retain one.
Perhaps the company should add a new sentence to its standard forward-looking disclaimer:
**“Actual CEO tenure may differ materially from management expectations.”**
Until then, shareholders can welcome the new appointment—while politely waiting for the 69-day safety and tolerability data.

بالكثير 8000 الغالبية تقريبا ليش؟؟

Vzla
Cmcl
Lode
Tmc
Help
Cntb
Crmd
Acon

الإلحاد واللا أدرية يناقضان العلم والعقل لأن الله عز وجل الموجد القادر هي الطريقة المنطقية الوحيدة التي تتماشى معها جميع المبادئ المنطقية والأسس العقلية التي تتماشى مع قوانين هذا الكون

أولا نشأة الكون والإنفجار العظيم :

هذا يثبت أن للكون بداية ومادام أنه له بداية فهناك من أوجده لأن العدم لايخلق شيئا واللاشيء لاينتج شيء

ثانيا الديناميكا الحرارية الثاني والتسلسل اللانهائي للطاقة

الذي ذهب إلى أن الطاقة لانهائية عبر تسلسل لانهائي اخطأ لأنه يناقض العلم فقانون الديناميكا الحرارية الثاني وهي أن الطاقة تسعى نحو الفوضى ولا يحدث العكس تلقائيا ابدا بمعنى لو كان هناك تسلسل لانهائي لما كنا في هذا التنظيم الحالي اللي نعيش فيه.

ثالثا التصميم الذكي وثابت بلانك يستحيل معه الصدفة لخلق هذا الكون

كل هذه الأدلة تدل على أن لهذا الكون خالق وموجد لم يأت من تلقاء نفسه ولم يحدث عبثا.

النفس دائما ماتميل الى الراحة والمتعة وتكره الكرف لذلك وازن والموازنة من اصعب الامور لانك ان دلعتها (والضمير عائد على النف) أدمنته وكان خروجك منه اصعب من دخوله وإن شددت عليها كرهتك فوازن واضبط والله يوفقكم في تحقيق اهدافكم مادامت لله وفي الله او في ما أحل الله

احس انها تحبني حاولت قبل فترة تاخذ رقم جوالي جاني فكرة اني اسألها عن مؤخرتي اذا حلوة بس بصراحة ايش ممكن المخاطر اللي تحصل من هذا الطلب اجيبوا بدون اساءة

المجتمع يرفضها لماذا؟ هل المجتمع يحب الشخصيات المنسوخة بمعنى نسخ متكررة في كل وقت؟؟

هل معقول في بنات عندهم هذا الفيتش في العالم العربي؟؟